SWOG clinical trial number

SWOG-7419

VP-16-213(4' Dm Methyl-Epipodophy LL-toxin-B-D Ethylidene Glucoside) in Adults with Metastatic Malignant Melanoma

Closed

Abbreviated Title

VP-16-213(4' Dm Methyl-Epipodophy LL-toxin-B-D Ethylidene Glucoside) in Adults with Metastatic Malignant Melanoma

Activated

08/23/1974

Closed

05/19/1975

Research committees

Melanoma

Other Clinical Trials

SWOG Clinical Trial Number

S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases

Research Committee(s)

Melanoma

Activated

09/23/2020

Accrual

91%

Open

Phase

SWOG Clinical Trial Number

CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Research Committee(s)

Melanoma

Activated

10/01/2018

Open

Phase

SWOG Clinical Trial Number

CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Research Committee(s)

Melanoma

Activated

09/10/2015

Open

Phase